| Autor: |
Grigoriev VB; CEA, Service de Neurovirologie, DSV/DRM/CRSSA/EPHE, Fontenay aux Roses, France., Adjou KT, Salès N, Simoneau S, Deslys JP, Seman M, Dormont D, Fournier JG |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of molecular neuroscience : MN [J Mol Neurosci] 2002 Jun; Vol. 18 (3), pp. 271-81. |
| DOI: |
10.1385/JMN:18:3:271 |
| Abstrakt: |
Amphotericine B (AmB), a macrolide polyene antibiotic, is one of a few drugs that has shown therapeutic properties in scrapie-infected hamster. Its beneficial effect on survival time is mostly marked when animals are treated with its derivative MS-8209. To explore the MS-8209 effect at the cellular level, we investigated at the light and electron microscopy levels, the sequential appearance and distribution of PrP concurrently with histopathological changes in hamsters that were infected intracerebrally with the 263 K scrapie strain and treated or not with the drug. The first histopathological modifications and PrP immunostaining were observed in the thalamus and at the inoculation site where the drug caused a delay in the appearance of lesions and PrP accumulation. Using immunoelectron microscopy, at 70 d postinfection, the inoculation site of untreated animals showed an accumulation of PrP in plaque areas constitued by filaments mixed with alterated membrane structures and in developed lysosomal system of reactive astrocytes. Most of the numerous lysosomes containing PrP showed intra-organelle filaments. In contrast, in MS-8209 treated animals, the number of lysosomes was significantly lower (p < 0.0038), with very few organelles harboring PrP. Our results suggest that in this scrapie model, MS-8209 treatment delays the disease by preventing the replication of the scrapie agent at the inoculation site where the astrocytes appear to be the first cells producing abnormal PrP. The lysosomal system of these astrocytes could constitute a privileged target for MS-8209. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink